Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Rhythm Biosciences Ltd. ( (AU:RHY) ) has issued an announcement.
Rhythm Biosciences has begun commercialising its ColoSTAT® blood test in Australia after securing ISO 15189:2022 accreditation, marking its first revenue-generating product and aiming to improve triage for more than 800,000 symptomatic colonoscopy patients annually, while easing pressure on the healthcare system. The company also advanced its geneType™ portfolio with early delivery of a next-generation colorectal cancer risk assessment test, peer-reviewed validation of its ovarian cancer model in Harvard’s large Nurses’ Health Study, new US-focused partnerships such as with CatchBio, and an evaluation agreement with NHS England, all underpinned by a strengthened balance sheet, removal of debt, and new board leadership as it shifts decisively from R&D to commercial growth.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.16 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian cancer diagnostics company focused on blood-based and predictive tests for early cancer detection. Its lead products include ColoSTAT®, a blood test aimed at improving triage for patients undergoing colonoscopy, and the geneType™ suite of risk assessment tests for cancers such as colorectal and ovarian, targeting both domestic and major international healthcare markets including the United States and the UK.
Average Trading Volume: 514,973
Technical Sentiment Signal: Buy
Current Market Cap: A$50.59M
For an in-depth examination of RHY stock, go to TipRanks’ Overview page.